Anavex Life SciencesAVXL
Market Cap: $478M
About: Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
Employees: 40
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
25% more call options, than puts
Call options by funds: $4.29M | Put options by funds: $3.44M
5% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 43
5% less funds holding
Funds holding: 146 [Q1] → 138 (-8) [Q2]
7.57% less ownership
Funds ownership: 39.2% [Q1] → 31.63% (-7.57%) [Q2]
29% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 28
31% less capital invested
Capital invested by funds: $163M [Q1] → $113M (-$49.8M) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Raghuram Selvaraju 43% 1-year accuracy 124 / 286 met price target | 609%upside $40 | Buy Reiterated | 1 Aug 2024 |
EF Hutton Jason Kolbert 43% 1-year accuracy 15 / 35 met price target | 716%upside $46 | Buy Maintained | 29 Jul 2024 |
EF Hutton Jason Kolbert 43% 1-year accuracy 15 / 35 met price target | 716%upside $46 | Buy Initiated | 22 Jul 2024 |